New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The state-of-the-art facility is equipped with best-in-class equipment and control systems
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The award recognizes powerful science–industry collaborations for social good
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Subscribe To Our Newsletter & Stay Updated
